Persistent infection with oncogenic human papillomavirus (HPV) types has been shown to be necessary for the development of cervical intraepithelial neoplasia (CIN) and cervical cancer ( 1 ). DNA testing for oncogenic HPV types has been proposed for primary screening, either alone or in combination with cytology; for triage of equivocal Papanicolaou (Pap) smears; and for surveillance and
management of patients after colposcopy ( 2 ) . However, the best way to implement HPV DNA testing in cervical cancer screening has not yet been established.
Current European guidelines for quality assurance in cervical cancer screening recommend implementation of a pilot program with a validated HPV DNA test within national organized cervical cancer screening programs and, if effective, permanent implementation of such programs ( 3 ) . Longitudinal studies that assess the incidence of high-grade cervical lesions (CIN 2 or CIN 3) and invasive cancer (as well as cross-sectional parameters of validity) are ultimately pivotal to defi ne the role of HPV DNA testing in cervical cancer screening policies ( 3 ) . However, only baseline results are available from most of the population-based randomized trials evaluating primary HPV DNA screening ( 4 -10 ) . In addition, longitudinal data from only two (to our knowledge) individual studies ( 11 , 12 ) and pooled data from seven European HPV screening studies have been reported ( 13 ) . There is compelling evidence of the cross-sectional effi cacy of HPV DNA testing in primary screening. In primary screening, HPV DNA testing has shown higher sensitivity but lower specifi city for the detection of CIN 2 or higher (CIN 2+) compared with conventional cytology ( 2 ) . The high sensitivity and high negative predictive value of HPV DNA testing for the detection of high-grade cervical lesions suggest that it could possibly be used to extend screening intervals ( 12 -15 ) . However, the low specifi city of an HPV DNA test alone would lead to increased numbers of follow-up tests and colposcopy referrals, which would simultaneously increase the adverse effects of screening.
Although the occurrence and progression of CIN and the sensitivity and specifi city of screening are age dependent, few studies have systematically evaluated the age-specifi c performance of primary HPV DNA screening ( 13 ) . Here, we report age-specifi c results for the cross-sectional validity and performance of primary HPV DNA testing compared with conventional cytology in the setting of an organized population-based cervical cancer screening program in Finland.
Materials and Methods

Study Design
In Finland, women between the age of 30 and 60 years are actively invited for cervical cancer screening every 5 years. Some municipalities invite women for cervical cancer screening beginning at age 25 years and/or up to age 65 years. The routine cervical screening program in Finland has been based on Pap smears; however, since 1999, technologically novel alternative tests have been implemented as primary screening tests with the aim of assessing their effectiveness ( 16 -18 ) . In particular, primary HPV DNA screening with a commercially available test to detect high-risk HPV DNA (Hybrid Capture 2; Qiagen, Inc, Gaithersburg, MD) was launched in 2003.
This study is based on routine invitations that were sent to Finnish women who were targeted for cervical screening within nine municipalities: in these, women were individually randomly assigned to receive an invitation to primary HPV DNA testing followed by cytology triage or to conventional cytological screening from January 1, 2003, to December 31, 2005. The design of the study is summarized in Figure 1 and has been described in detail elsewhere ( 9 , 17 , 19 ) .
This screening trial is registered as an International Standard Randomized Controlled Trial (trial number ISRCTN23885553). According to the principal Finnish authorities in medical and ethical issues, the National Authority for Medicolegal Affairs, and the ethical committee of the local hospital district and health boards of the municipalities, written informed consent from individuals included in this trial was not needed because the trial was conducted within the routine cervical cancer screening program. The same authorities gave the ethical approval for the trial.
Screening Tests
From women who were randomly assigned to the conventional screening arm, a cytological smear was taken with an Ayre spatula and a cytobrush and prepared on a glass slide according to standard procedures. The glass slide was subjected to routine staining, and the results were interpreted by a cytotechnician and classified
CONTEXT AND CAVEATS
Prior knowledge
Human papillomavirus (HPV) DNA testing is more sensitive than cytology for detecting cervical lesions, but it is uncertain whether the higher sensitivity depends on the age of the woman being screened.
Study design
A randomized study comparing the age-specific performance of primary HPV DNA screening with that of conventional cytological screening that was incorporated into the routine screening practice of Finland.
Contribution
Overall, primary HPV DNA screening with cytology triage was more sensitive than conventional screening for detecting cervical lesions. Among women younger than 35 years, those who got HPV DNA screening were referred for colposcopy more often than those who got conventional screening. Among women aged 35 years or older, HPV DNA testing with cytology triage was more sensitive and more specific than conventional screening, had a higher precision rate, and was associated with fewer colposcopy referrals and follow-up tests.
Implications
These results support the use of HPV DNA testing with cytology triage in primary cervical screening for women aged 35 years or older.
Limitations
Use of the conventional screening arm as the reference group may have affected the relative detection rates. Colposcopies were not done on the women who were HPV DNA positive but cytology triage negative nor on women who were negative for any test, resulting in verification bias. Laboratory personnel were aware of the screening test results. A considerable number of women in the HPV DNA screening arm were not screened according to the study protocol, which may have attenuated the performance of HPV DNA screening.
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Downloaded from https://academic.oup.com/jnci/article-abstract/101/23/1612/2515674 by guest on 12 April 2019 according to the modified Papanicolaou system, which includes a descriptive diagnosis. Slides with abnormal findings were reviewed by cytopathologists (including P. Nieminen, P. Laurila, and J. Tarkkanen) who worked in the two screening laboratories during the study period and who also reviewed a proportion (up to 10%) of the slides with normal findings. From women who were randomly assigned to the HPV DNA screening arm, cervical cells were collected with the cervical sampler brush included in the Hybrid Capture 2 test kit. The brush was fi rst used to prepare a cytological smear; then, the brush was placed into a tube containing Hybrid Capture 2 transport medium, and the tube was delivered to the screening laboratory. Staining and interpretation of cytological slides in the HPV DNA screening arm were identical to those in the conventional arm.
The transport medium containing the screening samples, that is, cervical cells including the possible HPV DNA, was processed with the supplies and reagents of the Hybrid Capture 2 assay in two screening laboratories. Probe cocktail B (Qiagen, Inc), which targets 13 high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), was used according to the manufacturer ' s instructions. Results of the HPV DNA detection assay were expressed as a ratio of relative light units (rlu ratio) to the average of three positive controls, with 1.00 (equivalent to HPV DNA concentration of 1 pg/mL) as the cutoff for test positivity (ie, a rlu ratio ≥ 1.00 was considered HPV DNA positive, and a rlu ratio <1.00 was considered HPV DNA negative). The test cutoff and internal quality assurance procedures were according to the manufacturer's instructions.
Triage and Diagnostic Procedure
Cytological smears taken from women in the HPV DNA screening arm were analyzed only for the women whose primary HPV DNA test was positive. The cytotechnicians who interpreted the smears and the cytopathologists who reviewed the abnormal findings were aware of the HPV DNA test result. Cytological analysis was also carried out for women in the HPV DNA screening arm whose HPV DNA sample was not available (n = 2737). The vast majority of the missing DNA samples were because of technical reasons (eg, proper brush or tube was missing, or the sample was erroneously not taken). Less frequently, the woman refused consent for the HPV DNA test.
Cytological and histological criteria for defi ning abnormalities were the same in both screening arms. The threshold for a cytological abnormality was Papanicolaou class II (which roughly corresponds to a reactive abnormality or atypical squamous cells of undetermined signifi cance [ASCUS]). Women with an abnormal smear were recommended for intensifi ed follow-up and rescreening after 12 months, unless an immediate colposcopy was recommended by the cytopathologist.
Women with a cytological abnormality classifi ed as Papanicolaou classes III -V, which correspond to a low-grade squamous intraepithelial lesion (LSIL) or more severe abnormality, were referred for colposcopy and biopsy. Referrals followed the policy that has been offi cially recommended by the Finnish guidelines on diagnosis and treatment of CIN since August 2006 ( www . kaypahoito . fi [links to English versions are available at this site]). Women who were referred for colposcopy on the basis of Papanicolaou class III or more severe (LSIL or more severe) cytology following a positive HPV DNA test result in the HPV DNA screening arm, or Papanicolaou class III or more severe cytology in the conventional screening arm, but who did not have histologically confi rmed CIN were also targeted for intensifi ed follow-up, as were the women in the HPV DNA screening arm who were high-risk HPV DNA positive but had normal or borderline cytology.
Colposcopies were conducted according to routine procedures in local hospitals, where the biopsy specimens were also analyzed. Colposcopists and pathologists involved in diagnostic procedures had access to the patient's medical records, including their screening test results. Histology was graded using three-tiered designation for CIN, in which CIN 1 is mild dysplasia, CIN 2 is moderate dysplasia, and CIN 3 is severe dysplasia and carcinoma in situ (including adenocarcinoma in situ).
During the study period, all CIN 1+ cervical lesions detected within the screening program were treated, usually with the loop electrosurgical excision procedure. After December 31, 2006, a high-grade cervical lesion (ie, CIN 2+) was always treated, whereas women younger than 30 years with CIN 1 lesions were usually managed with surveillance only until the lesions regressed or were treated if progression occurred ( www . kaypahoito . fi ).
Statistical Analysis
Cross-sectional (or relative) sensitivity between arms was calculated from the number of screen-detected cervical lesions divided by the total number of women screened. Differences in relative sensitivity in the HPV DNA arm vs conventional arm were estimated using age-specific relative rates (RRs) of detection for histological endpoints of CIN 1, CIN 2, CIN 3+, and any CIN or cancer ( 1 , 3 ).
Positive predictive values (PPVs) were calculated from the number of histologically confi rmed cervical lesions divided by the number of women with a positive screen. A positive screen, that is, test positive, in the HPV DNA screening arm had two defi nitions: 1) women whose cytology triage test was positive (referral for colposcopy) and 2) women whose primary screening test was positive (a recommendation for intensifi ed follow-up). Poisson regression analyses were performed to assess relative rates (RRs) with 95% confi dence intervals (CIs) for test positivity and histological confi rmation in the HPV DNA screening arm by using the conventional screening arm as the referent group. For this analysis, time at risk was specifi ed as 1 for each subject, that is, for each screening visit ( 20 ) .
In addition to the crude estimates, we report estimates stratifi ed by age group (25 -34, 35 -44, 45 -54, or ≥ 55 years old). These age groups were chosen because they represent women at different phase of life, for example, young and fertile women, subfertile women, menopausal women (early middle age), and postmenopausal women (late middle age), for whom screening recommendations are likely to differ.
Specifi city estimates of the screening test were calculated as the number of women with a negative screening test divided by the number of disease-free subjects (ie, the total number of women screened minus the number of women who had histologically confi rmed cervical lesion). In the HPV DNA screening arm, two different defi nitions for a negative screen were used: 1) women whose cytology triage test was negative (no referral for colposcopy) and 2) women whose primary screening test was negative (no recommendation for intensifi ed follow-up). Comparison of the specifi city estimates between the screening arms was performed by modeling for age-specifi c false positivity rates (1 minus specifi city) using Poisson regression analysis. Specifi cities as well as PPVs were calculated using histological endpoints of CIN 1 or higher (CIN 1+), CIN 2 or higher (CIN 2+), and CIN 3 or higher (CIN 3+).
The association between the outcome and age was tested using Poisson regression, with the trial arm, age, and the trial arm -age interaction as covariates. All of the major analyses were conducted on an intention-to-screen basis, which is valid for public healthoriented estimates. All statistical tests were two-sided, and a P value less than or equal to .05 was considered statistically significant. All statistical analyses were performed with Stata software, release 10.0 (StataCorp LP, College Station, TX).
Results
A total of 108 425 randomized invitations to routine cervical cancer screening were sent: 54 207 invitations were for HPV DNA screening and 54 218 were for conventional cytology screening. Of those invited, 35 837 women (66.1%) attended screening in the HPV DNA screening arm and 35 500 (65.5%) attended in the conventional screening arm ( Figure 1 ). The attendees in the HPV DNA and the conventional screening arms were of similar age (mean age: 45.2 and 45.3 years, respectively) and were similar in terms of their place of residence, screening laboratory, marital status, and parity (data not shown).
In the HPV DNA screening arm, 33 100 women (92.4%) received primary screening with the HPV DNA test and 2737 women (7.6%) received primary screening with cytology ( Figure 1 ).
In the HPV DNA screening arm, 2628 women (7.3% of those screened) were positive for high-risk HPV DNA, of whom 2626 underwent triage testing by cytology. In addition, in the HPV DNA screening arm, 3436 women who were HPV DNA negative underwent cytological analysis because they reported abnormal bleeding symptoms at the screening visit (data not shown). In the conventional screening arm, 35 475 women (99.9%) received primary screening with cytology.
Among the 5363 women in the HPV DNA screening arm who had cytology analyzed (2626 women with cytology triage and 2737 women with primary cytology), 7.9% had LSIL or a more severe fi nding, 21.8% had ASCUS or reactive changes or a more severe fi nding, and 77.9% had normal cytology. Among the 35 479 women in the conventional screening arm who had cytology analyzed (35 475 women with primary cytology and four women with cytology triage), 1.2% had LSIL or a more severe fi nding, 7.0% had ASCUS or reactive changes or a more severe fi nding, and 92.7% had normal cytology. Because only 2737 primary cytology tests were done in the HPV DNA arm, there was no material difference in the distribution of the cytological results in comparison to the conventional arm (0.9% LSIL or a more severe fi nding, 6.1% ASCUS or reactive changes or a more severe fi nding, and 93.5% normal cytology in the HPV DNA arm). The number of uninterpretable Pap smears was low in each screening arm (16 in the HPV DNA screening arm vs 79 in the conventional screening arm). Age-specifi c screening test results are detailed in Table 1 . A total of 2581 women (7.2%) in the HPV DNA screening arm were recommended for intensifi ed follow-up compared with 2340 women (6.6%) in the conventional screening arm, that is, there were 9% more intensifi ed follow-up recommendations in the HPV DNA screening arm overall (95% CI = 3% to 15%). Most intensifi ed follow-up recommendations in the HPV DNA screening arm were based on a positive HPV DNA test result (n = 2228 women); other reasons for an intensifi ed follow-up recommendation were an abnormal cytology result (n = 142) or a normal colposcopy and histopathology result (n = 211).
In both screening arms, the percentage of women who were recommended for intensifi ed follow-up was highest for those aged 25 -29 years (21.9% of 25-to 29-year-olds in the HPV DNA screening arm and 10.0% of 25-to 29-year-olds in the conventional screening arm) ( Figure 2, A ) . In both arms, the percentage of women who were recommended for intensifi ed follow-up decreased with increasing age, and from the age of 40 years onward, the percentage was consistently lower in the HPV DNA screening arm than in the conventional screening arm. The percentage of follow-up recommendations was statistically significantly associated with age in both screening arms ( P for age and P trend < .001). Among women aged 25 -34 years, 15.8% of the screened women were targeted for intensifi ed follow-up, and the relative rate of intensifi ed follow-up in the HPV DNA screening arm vs the conventional screening arm was 2.20 (95% CI = 1.96 to 2.47).
The overall frequency of colposcopy referrals was 1.2% in both screening arms (RR = 1.00, 95% CI = 0.87 to 1.14). The colposcopy referral rates varied somewhat across the age groups ( P for age < .001) even though we observed no systematic pattern of referral by age ( Figure 2, B ) . Among women younger than 35 years, there were 27% more colposcopy referrals (95% CI = 1% to 60%) in the HPV DNA screening arm than in the conventional screening arm.
The prevalence of histologically confi rmed CIN or cancer was 0.59% in the HPV DNA screening arm vs 0.43% in the conventional screening arm, and CIN 2 lesions were the most common fi ndings in both arms ( Table 2 ). The relative rates of detection for CIN 1, CIN 2, and CIN 3+ in the HPV DNA screening vs conventional screening arm were 1.44 (95% CI = 0.99 to 2.10), 1.39 (95% CI = 1.03 to 1.88), and 1.22 (95% CI = 0.78 to 1.92), respectively. Overall, there were 37% more cervical lesions (any CIN or cancer) (95% CI = 11% to 69%) detected in the HPV arm than in the conventional arm ( Table 3 ) . However, we observed no patterns in the relative rates of detection for any of the histological outcomes with respect to age ( Table 3 ) .
For every histological outcome, the specifi city of the HPV DNA test with cytology triage, for all age groups, was about the same as that of cytology screening, whereas the specifi city of the HPV DNA test alone was clearly inferior (eg, the specifi city of the HPV DNA testing with cytology triage for CIN 2+ was 99.2%, whereas the specifi cities of the HPV DNA test alone and cytology were 93.0% and 99.1%, respectively) ( Table 4 ) . Over all ages, the specifi city of HPV DNA testing with cytology triage was statistically signifi cantly higher than that of cytological screening for CIN 1+ ( P = .009), whereas for CIN 2+ and CIN 3+, there was no difference in specifi city between screening methods ( P = .13 and P = .79, respectively) ( Table 4 ) . In both screening arms and for all histological outcomes, the rate of a false-positive screening test result decreased statistically significantly with increasing age, that is, the specifi city of the screening test increased with increasing age ( P for age < .001; Table 4 ). HPV DNA screening with cytology triage tended to have better specifi city than conventional screening for all lesions among all age groups of women 35 years or older in the screening population; for example, the specifi city of the HPV DNA testing with cytology triage for CIN 2+ was 99.0% for 35-to 44-year-olds, 99.6% for 45-to 54-year-olds, and 99.6% for those aged 55 years or older, whereas the specifi cities of conventional cytology for CIN 2+ in these age groups were 98.9%, 99.3%, and 99.5%, respectively ( Table 4 ). The specifi city of the HPV DNA test alone also increased with increasing age; however, in all age groups, the specifi city of the HPV DNA test alone was statistically significantly lower than that of conventional cytology ( P < .001 for CIN 1+, CIN 2+, and CIN 3+) ( Table 4 ) . Finally, the PPVs for HPV DNA testing with cytology triage were consistently higher than those for conventional screening for all studied histological outcomes. The relative PPV for the HPV DNA screening arm vs the conventional screening arm for CIN 1+ was 1.37 (95% CI = 1.11 to 1.69), for CIN 2+ was 1.34 (95% CI = 1.04 to 1.72), and for CIN 3+ was 1.22 (95% CI = 0.78 to 1.92). The PPV of the HPV DNA test alone was poor and ranged from Furthermore, the association between PPV and age decreased with increasing stage of malignancy ( P for age < .001 for CIN 1+, P for age = .005 for CIN 2+, and P for age = .20 for CIN 3+; Table 5 ).
Discussion
To our knowledge, this is the first prospective randomized controlled study to compare primary cervical screening by HPV DNA testing with primary cervical screening by conventional cytology by age throughout the entire age range covered by population-based screening programs. Our cross-sectional data from the recruitment screen (ie, the first screening visit following the invitation letter since randomization into HPV DNA or conventional screening) showed that HPV DNA testing with cytology triage was more sensitive than conventional cytology in detecting CIN 1 and CIN 2 lesions. Although HPV DNA testing with cytology triage was also more sensitive than conventional cytology in detecting CIN 3 lesions, the difference in the relative rates of detection between these screening arms was not statistically significant. The most striking fi nding was that among women aged 35 years or older, primary HPV DNA screening with cytology triage was not only more sensitive than conventional screening but also more specifi c and had a better PPV. However, there was a very high rate of recommendation for intensifi ed follow-up (ie, women whose primary screening test was positive) in the HPV DNA arm among the younger women (those aged 25 -34 years) targeted by the program (see below). This high number of women with a positive primary screening test result may lead to larger adverse effects of screening if more unnecessary follow-up recommendations are made or nonprogressive lesions are detected and treated.
Previous studies have shown that the relative sensitivity of HPV DNA testing vs conventional screening is higher for women younger than 30 or 35 years than for older women ( 13 , 21 -23 ) . In this study, an excess of CIN 1 lesions was detected in the HPV DNA screening arm among the youngest targeted women (ie, those aged 25 -34 years). In addition, CIN 1 and CIN 2 detection rates were also increased in the HPV DNA screening arm compared with conventional cytology arm among women aged 35 -44 years. Increased detection of CIN 1 and CIN 2 lesions in this age group may lead to the earlier diagnosis of high-grade cervical lesions, which was suggested by HPV DNA screening follow-up studies from Sweden ( 11 ), the Netherlands ( 12 ), and a joint European cohort ( 13 ) .
Earlier detection with HPV DNA screening may indicate higher screening effectiveness over many screening rounds as lesions detected and treated early are not likely to reappear in subsequent screening rounds. Nevertheless, careful age-based selection of the women to be screened may be warranted because in Sweden, there was no statistically signifi cant reduction in CIN 2 lesions in subsequent screening rounds, suggesting that at least some of the increased sensitivity at the initial screen might represent overdiagnosis of clinically insignifi cant CIN 2 lesions, as was also concluded by the ASCUS -LSIL Triage Study group ( 24 ). The issue of overdiagnosis and overmanagement is of particular importance for women of reproductive age because it has been shown that rate of serious obstetrical complications, such as preterm deliveries, is increased after excisional treatments for precancerous lesions ( 25 , 26 ) . In addition, adverse effects of such treatments with respect to fertility cannot be totally ruled out ( 25 ) .
Cross-sectional specifi city estimates are relevant for estimating potential differences in some adverse effects and cost between the screening tests in the screening program. The specifi city of the HPV DNA testing with cytology triage for CIN 2+ was 99.2%, whereas the specifi cities of the HPV DNA test alone and cytology were 93.0% and 99.1%, respectively. All of the specifi city estimates in this study were slightly higher than those reported in a thorough overview of meta-analyses and systematic reviews on the cross-sectional performance of primary HPV DNA screening ( 2 ) . This difference in specifi city estimates may be partially explained by differences in the designs of HPV DNA screening studies: This study included cytology triage, whereas other studies used either an HPV DNA test alone or combined the HPV DNA test and cytology. Our specifi city estimates, PPVs, and colposcopy referral rates were most similar to those reported for the Canadian Cervical Cancer Screening Trial ( 10 ) , in which double testing was used, but the sequence of primary and triage test was randomly assigned, that is, either HPV DNA test with cytology triage or cytology with HPV DNA triage, of which the former allows a comparison with our study. * Number of histologically confirmed lesions by age within screening arms is given in Table 2 . CI = confidence interval; CIN 1 = cervical intraepithelial neoplasia grade 1; CIN 2 = CIN grade 2; CIN 3+ = CIN grade 3 or more severe; HPV = human papillomavirus. † Likelihood ratio test (two-sided). Referent * Specificity estimates calculated from the number of test-negative subjects divided by the number of disease-free subjects, that is, the total number of women screened minus the number who were histology positive. P values for the association between the specificity and the age were calculated for both screening arms combined. All P values are from the likelihood ratio test (two-sided).
-= not applicable; CI = confidence interval; CIN 1+ = cervical intraepithelial neoplasia grade 1 or more severe; CIN 2+ = CIN grade 2 or more severe; CIN 3+ = CIN grade 3 or more severe; HPV = human papillomavirus; RR = relative rate. † For the HPV DNA screening arm, specificity estimates and relative rates are calculated for two definitions for screening test negativity: no referral for colposcopy (cytology triage negative) and primary HPV DNA screening test negative. ‡ Ninety-five percent confidence intervals calculated by using binomial probability law. § The specificity of HPV DNA testing with cytology triage or the primary HPV DNA screening test vs the specificity of conventional cytology screening. results. Awareness of the negative or positive HPV DNA test result may have affected the criteria for defi ning abnormalities because the interpretation of both cytology and histology is subjective, and this may partially explain the higher referral and detection rates seen in the HPV DNA screening arm. However, the same bias is likely to occur whenever HPV DNA screening is incorporated into routine health care, and one of our study aims was to compare the different methods in routine practice. Long-term follow-up of the women included in this study will ultimately reveal the size of the bias. Finally, this study was analyzed mainly on an intention-to-screen basis, which is the relevant approach for public health studies. A considerable number of women in the HPV DNA screening arm were not screened according to the study protocol, which is typical in studies of public health-care activities. Misclassifi cation of disease status by the actual screening test was similar in both study arms, and hence, our results might be attenuated compared with results of perprotocol analyses that are restricted to women who received the screening approach intended for the study arm.
In countries like Finland that have a well-organized cervical screening program and low incidence of cervical cancer, new interventions are expected to provide only small increases in a screening program's effi cacy ( 19 ) . Nevertheless, our results support the use of HPV DNA testing with cytology triage in primary cervical screening. The cross-sectional performance of primary HPV DNA screening with cytology triage was similar to that of conventional screening and was particularly good among women aged at least (or preferably older than) 35 years, even though this restriction has been challenged ( 8 ) . Both screening methods can be used in a population-based screening program. Long-term follow-up is needed to ultimately decide about whether to use HPV DNA screening in women younger than 35 years, as well as whether to use routine HPV DNA screening without cytology triage at any age. It is likely that these interventions would lead to increased detection of mild lesions, and consequently, the possible adverse effects of overtreatment have to be evaluated.
